Innocare Pharma's Zorifertinib Tablets Included in 2026 National Medical Insurance Catalog

Stock News
3 hours ago

Innocare Pharma Limited (SSE: 688428) has announced that its independently developed next-generation TRK inhibitor Zorifertinib Tablets (brand name: Yinuoxin®) has been included in the new version of the National Medical Insurance Catalog, for the treatment of adult and adolescent patients aged 12 and above with solid tumors carrying NTRK fusion genes.

The new version of the National Medical Insurance Catalog will officially take effect on January 1, 2027. The agreement is valid from January 1, 2027 to December 31, 2028.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10